Hybrid Macrocyclic Peptides — Synthetic Strategies to Diversify and Cyclize Peptide Libraries in Phage Display Selections
- 1Stratingh Institute for Chemistry University of Groningen Groningen The Netherlands
Abstract
Macrocyclic peptides (MPs) are privileged molecular architectures in drug discovery that combine the target selectivity of biologics with the pharmacological advantages of small molecules. However, peptide binders identified by biological selection platforms such as bacteriophage display often require extensive post‐selection medicinal chemistry optimization before entering the clinic. In particular, the incorporation of nonpeptidic scaffolds and synthetic cyclization units is frequently necessary to improve binding affinity, proteolytic stability, membrane permeability, and overall pharmacological performance. In this Review, we provide a comprehensive overview and critical analysis of strategies that enable the direct selection of such hybrid MPs by bacteriophage display. We discuss established cysteine‐ and lysine‐targeting chemistries, recent advances in residue‐selective and chemoenzymatic cyclization methods, and emerging approaches that exploit proximity‐driven reactivity or the chemical sturdiness of bacteriophages. Collectively, these strategies enable the simultaneous exploration of peptide sequence and synthetic chemical space during biological selections, thereby potentially reducing downstream optimization efforts. Finally, we outline key design principles for phage‐compatible macrocyclization reactions and discuss future opportunities at the interface of bioconjugation chemistry, enzyme engineering, and machine‐learning‐guided peptide discovery to accelerate the development of next‐generation peptide therapeutics.
Related
- Evolving strategies for lineage tracing: Genetic markers, synthetic barcodes, and natural variants
- Sequence‐encoded dynamics diversify allostery within a conserved protein scaffold
- Protein cofactors diversify PRC2 architecture and function
- Discovery of an NRAS isoform and activation-state selective macrocyclic peptide
- Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development
BibTeX
@article{oppewal2026hybrid,
title = {{Hybrid Macrocyclic Peptides — Synthetic Strategies to Diversify and Cyclize Peptide Libraries in Phage Display Selections}},
author = {Titia Rixt Oppewal and Clemens Mayer},
journal = {Chemistry (Weinheim an Der Bergstrasse, Germany)},
year = {2026},
month = jul,
doi = {10.1002/chem.71408},
url = {https://doi.org/10.1002/chem.71408},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Hybrid Macrocyclic Peptides — Synthetic Strategies to Diversify and Cyclize Peptide Libraries in Phage Display Selections
AU - Titia Rixt Oppewal
AU - Clemens Mayer
PY - 2026
DA - 2026/07/14
JO - Chemistry (Weinheim an Der Bergstrasse, Germany)
DO - 10.1002/chem.71408
UR - https://doi.org/10.1002/chem.71408
AB - Macrocyclic peptides (MPs) are privileged molecular architectures in drug discovery that combine the target selectivity of biologics with the pharmacological advantages of small molecules. However, peptide binders identified by biological selection platforms such as bacteriophage display often require extensive post‐selection medicinal chemistry optimization before entering the clinic. In particular, the incorporation of nonpeptidic scaffolds and synthetic cyclization units is frequently necessary to improve binding affinity, proteolytic stability, membrane permeability, and overall pharmacological performance. In this Review, we provide a comprehensive overview and critical analysis of strategies that enable the direct selection of such hybrid MPs by bacteriophage display. We discuss established cysteine‐ and lysine‐targeting chemistries, recent advances in residue‐selective and chemoenzymatic cyclization methods, and emerging approaches that exploit proximity‐driven reactivity or the chemical sturdiness of bacteriophages. Collectively, these strategies enable the simultaneous exploration of peptide sequence and synthetic chemical space during biological selections, thereby potentially reducing downstream optimization efforts. Finally, we outline key design principles for phage‐compatible macrocyclization reactions and discuss future opportunities at the interface of bioconjugation chemistry, enzyme engineering, and machine‐learning‐guided peptide discovery to accelerate the development of next‐generation peptide therapeutics.
SN - 0947-6539
SN - 1521-3765
ER -